摘要
目的探索促红细胞生成素产生肝细胞激酶受体B6(Eph B6)蛋白在结直肠癌中表达及其临床意义。方法采用免疫组织化学染色方法检测一组结直肠癌组织中Eph B6蛋白表达,分析其与临床病理指标以及患者总生存时间之间的关系。结果正常黏膜组织Eph B6蛋白阳性表达率为75.0%(93/124),腺瘤型息肉为73.7%(42/57),结直肠癌组织中为54.0%(67/124),Eph B6在结直肠癌中的表达显著低于腺瘤和正常黏膜(P<0.05)。Eph B6蛋白在癌组织中表达与肿瘤分化(P<0.01)、淋巴结转移(P<0.01)和Dukes分期(P<0.01)有关;但与结直肠癌患者的年龄、性别和部位无关。Eph B6低表达患者比高表达患者预后差(P<0.05)。结论 Eph B6在结直肠癌发生、发展和预后中可能具有抑癌基因的作用,可能成为一种新的肿瘤预后和治疗靶点。
Objective To explore the clinical significance of decreased expression of EphB6 receptor tyrosine kinase in color-ectal carcinoma. Methods A set of colorectal carcinoma samples was detected the expression of EphB6 by using immunohistochemical staining. The relationship between the expression of EphB6 and clinicopathological parameters and survival was analyzed. Results The EphB6 expression was detected in normal mucosa （75.0%, 93/124）, adenoma （73.7%, 42/57）, colorectal carcinoma （54.0%, 67/124） . The expression level of EphB6 was significantly decreased in colorectal cancer compared with adenoma and normal mucosa （ P〈0.05）. The decreased expression of EphB6 was significantly associated with differentiation （P〈0.01）, lymph node metastasis（P〈0.01） and Dukes stage （ P〈0.01） . There was no significant difference between the expression of EphB6 and age, sex, and tumor loca-tion. The patients with decreased expression of EphB6 had a poor survival （ P〈0.05） . Conclusion EphB6 may have a tumor suppres-sor role in colorectal carcinoma and may be a new target for therapy.
出处
《东南国防医药》
2016年第4期346-348,共3页
Military Medical Journal of Southeast China
基金
国家自然基金(81371611)
